FDA Adds To Unapproved Drug Initiative Scorecard With Action Against KV
Two weeks after FDA officials attempted to explain how well the Center for Drug Evaluation and Research's unapproved drug initiative is working, the agency showed how action often speaks louder than words
You may also be interested in...
Already plagued by scandal, KV Pharma is subject to NYSE delisting if overdue 2009 annual report is not filed soon.
Certain products will not be distributed until approved via NDA or ANDA processes.
Firm halts manufacturing and distribution of nearly all products.